Will CRISPR fears fade with familiarity?
By Patricia Stapleton,
The Conversation
| 08. 21. 2017
The first “test-tube baby” made headlines around the world in 1978, setting off intense debate on the ethics of researching human embryos and reproductive technologies. Every breakthrough since then has raised the same questions about “designer babies” and “playing God” – but public response has grown more subdued rather than more engaged as assisted reproductive technologies have become increasingly sophisticated and powerful.
As the science has advanced, doctors are able to perform more complex procedures with better-than-ever success rates. This progress has made in vitro fertilization and associated assisted reproductive technologies relatively commonplace. Over one million babies have been born in the U.S. using IVF since 1985.
And Americans’ acceptance of these technologies has evolved alongside their increased usage, as we’ve gotten used to the idea of physicians manipulating embryos.
But the ethical challenges posed by these procedures remain – and in fact are increasing along with our capabilities. While still a long way from clinical use, the recent news that scientists in Oregon had successfully edited genes in a human embryo brings us...
Related Articles
By Alistair Sponsel and Brian Sutton, Springer Nature | 10.05.2026
This essay, co-authored by a historian of science and an X-ray crystallographer, sheds new light on Rosalind Franklin’s Photograph 51. We refute the infamous claim that, unlike James Watson, Franklin failed to see the picture’s potential significance for interpreting the...
By Andrea Martani, BioNews | 10.05.2026
In July 2026, PET and ESHRE published a joint report containing the results of an international survey assessing public attitudes towards the use of embryos in the context of fertility treatment and research. Societal views on these matters are considered...
By Rob Stein, NPR [cites CGS' Katie Hasson] | 09.29.2026
Cathy Tie slips on a white lab coat bearing her name and the logo of her startup: Origin Genomics. "Welcome!" she says as she leads an NPR reporter, photographer and videographer on an exclusive tour of Origin's labs located...
By Ryan Cross, Endpoints News | 09.02.2026
The deaths of two children who received CRISPR therapies in China have rattled scientists who work on similar genetic medicines in the US, adding new fuel to a yearslong debate about the danger of the gene therapy field’s most-used delivery...